华森制药：苍耳子鼻炎胶囊完成境内生产药品备案

Core Viewpoint - The company Huason Pharmaceutical (002907) has announced that its product Cang'erzi Nasal Capsule has completed the domestic production drug filing, which includes an application for an extension of the drug's validity period [1] Group 1 - The product Cang'erzi Nasal Capsule is now officially registered for production in China [1] - The announcement indicates a strategic move to extend the product's market presence through an extended validity period [1]